One reference was about mortality and cancer incidence in acromegaly (Orme et al., 1998), one focused on long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly, and one was about the treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant (Trainer et al., 2000). This evidence concerns the gene GHR and acromegaly.